

Jorge B L Cannata-Andr a

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/738685/publications.pdf>

Version: 2024-02-01

204
papers

12,085
citations

24978

57
h-index

29081

104
g-index

211
all docs

211
docs citations

211
times ranked

10866
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2004, 350, 459-468.	13.9	1,465
2	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1346-1359.	0.4	628
3	Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 674.	3.8	495
4	A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4263-4272.	0.4	460
5	Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). <i>Osteoporosis International</i> , 2003, 14, 19-26.	1.3	251
6	Large-Scale Analysis of Association Between <i>LRP5</i> and <i>LRP6</i> Variants and Osteoporosis. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1277.	3.8	246
7	Nutritional status in dialysis patients: a European consensus. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 563-572.	0.4	206
8	Mortality Associated with Vertebral Deformity in Men and Women: Results from the European Prospective Osteoporosis Study (EPOS). <i>Osteoporosis International</i> , 1998, 8, 291-297.	1.3	197
9	Incidence of Limb Fracture across Europe: Results from the European Prospective Osteoporosis Study (EPOS). <i>Osteoporosis International</i> , 2002, 13, 565-571.	1.3	191
10	Osteoporosis in chronic kidney disease. <i>American Journal of Kidney Diseases</i> , 2004, 43, 566-571.	2.1	189
11	Oral active vitamin D is associated with improved survival in hemodialysis patients. <i>Kidney International</i> , 2008, 74, 1070-1078.	2.6	183
12	Bone Density Variation and Its Effects on Risk of Vertebral Deformity in Men and Women Studied in Thirteen European Centers: The EVOS Study. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1883-1894.	3.1	177
13	Validity of Self-Report of Fractures: Results from a Prospective Study in Men and Women Across Europe. <i>Osteoporosis International</i> , 2000, 11, 248-254.	1.3	177
14	Progression of vascular calcifications is associated with greater bone loss and increased bone fractures. <i>Osteoporosis International</i> , 2008, 19, 1161-1166.	1.3	169
15	Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 723-731.	0.4	162
16	Health-related quality of life and radiographic vertebral fracture. <i>Osteoporosis International</i> , 2004, 15, 113-119.	1.3	161
17	Prevalent Vertebral Deformity Predicts Incident Hip though not distal Forearm Fracture: Results from the European Prospective Osteoporosis Study. <i>Osteoporosis International</i> , 2001, 12, 85-90.	1.3	159
18	Population-based geographic variations in dxa bone density in Europe: The evos study. <i>Osteoporosis International</i> , 1997, 7, 175-189.	1.3	148

#	ARTICLE	IF	CITATIONS
19	Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1542-1551.	0.4	140
20	SYSTEMIC ALUMINUM TOXICITY: EFFECTS ON BONE, HEMATOPOIETIC TISSUE, AND KIDNEY. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 1996, 48, 649-666.	1.1	137
21	Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2846-2850.	0.4	137
22	Use of phosphate-binding agents is associated with a lower risk of mortality. <i>Kidney International</i> , 2013, 84, 998-1008.	2.6	136
23	The Effects of Lifestyle, Dietary Dairy Intake and Diabetes on Bone Density and Vertebral Deformity Prevalence: The EVOS Study. <i>Osteoporosis International</i> , 2001, 12, 688-698.	1.3	135
24	Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1938-1947.	0.4	133
25	Vascular Calcifications: Pathogenesis, Management, and Impact on Clinical Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S267-S273.	3.0	131
26	High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. <i>Bone</i> , 2010, 46, 121-128.	1.4	127
27	Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences. <i>International Journal of Molecular Sciences</i> , 2021, 22, 408.	1.8	125
28	Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. <i>Kidney International</i> , 2016, 90, 77-89.	2.6	120
29	Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 239-246.	0.4	118
30	The connections between vascular calcification and bone health. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3429-3436.	0.4	116
31	Reproducibility of a Questionnaire on Risk Factors for Osteoporosis in a Multicentre Prevalence Survey: The European Vertebral Osteoporosis Study. <i>International Journal of Epidemiology</i> , 1994, 23, 559-565.	0.9	113
32	Cancer-associated bone disease. <i>Osteoporosis International</i> , 2013, 24, 2929-2953.	1.3	113
33	The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. <i>Osteoporosis International</i> , 2003, 14, 520-524.	1.3	112
34	Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. <i>American Heart Journal</i> , 2012, 164, 902-909.e2.	1.2	112
35	Back pain, disability, and radiographic vertebral fracture in European women: a prospective study. <i>Osteoporosis International</i> , 2004, 15, 760-765.	1.3	106
36	Vitamin D status and secondary hyperparathyroidism: The importance of 25-hydroxyvitamin D cut-off levels. <i>Kidney International</i> , 2003, 63, S44-S48.	2.6	95

#	ARTICLE	IF	CITATIONS
37	Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. <i>Current Medical Research and Opinion</i> , 2003, 19, 383-394.	0.9	94
38	Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: The GENOMOS study. <i>Bone</i> , 2008, 42, 969-981.	1.4	91
39	Indirect Regulation of PTH by Estrogens May Require FGF23. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2009-2017.	3.0	89
40	Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. <i>Bone</i> , 2005, 36, 387-398.	1.4	88
41	Erythropoietin in chronic renal failure. <i>Kidney International</i> , 1996, 50, 1373-1391.	2.6	83
42	The position of strontium ranelate in today's management of osteoporosis. <i>Osteoporosis International</i> , 2015, 26, 1667-1671.	1.3	81
43	Survey response rates: national and regional differences in a European multicentre study of vertebral osteoporosis.. <i>Journal of Epidemiology and Community Health</i> , 1995, 49, 87-93.	2.0	79
44	COSMOS: the dialysis scenario of CKD-MBD in Europe. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1922-1935.	0.4	79
45	The clinical impact of aluminium overload in renal failure. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 9-12.	0.4	78
46	Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1415-1422.	0.4	74
47	MicroRNAs 29b, 133b, and 211 Regulate Vascular Smooth Muscle Calcification Mediated by High Phosphorus. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 824-834.	3.0	71
48	Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management. <i>Calcified Tissue International</i> , 2021, 108, 410-422.	1.5	71
49	A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: part 2: renal replacement therapy. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2940-2945.	0.4	70
50	Management of osteoporosis in the elderly. <i>Current Medical Research and Opinion</i> , 2009, 25, 2373-2387.	0.9	69
51	The influence of family history of hip fracture on the risk of vertebral deformity in men and women: The European vertebral osteoporosis study. <i>Bone</i> , 1997, 20, 145-149.	1.4	65
52	Role of iron metabolism in absorption and cellular uptake of aluminum. <i>Kidney International</i> , 1991, 39, 799-803.	2.6	64
53	EGFR Activation Increases Parathyroid Hyperplasia and Calcitriol Resistance in Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 310-320.	3.0	63
54	Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3731-3737.	0.4	62

#	ARTICLE	IF	CITATIONS
55	Necrotic Concentrations of Cisplatin Activate the Apoptotic Machinery but Inhibit Effector Caspases and Interfere with the Execution of Apoptosis. <i>Toxicological Sciences</i> , 2011, 122, 73-85.	1.4	60
56	European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2162-2166.	0.4	59
57	Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2735-2744.	0.4	59
58	Adynamic Bone and Chronic Renal Failure: An Overview. <i>American Journal of the Medical Sciences</i> , 2000, 320, 81-84.	0.4	56
59	Reference Values for Trace and Ultratrace Elements in Human Serum Determined by Double-Focusing ICP-MS. <i>Biological Trace Element Research</i> , 2001, 82, 259-272.	1.9	55
60	Photoacoustic Imaging With a Commercial Ultrasound System and a Custom Probe. <i>Ultrasound in Medicine and Biology</i> , 2011, 37, 484-492.	0.7	53
61	Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1736-1738.	0.5	52
62	Vitamin D Receptor Gene Polymorphisms, Bone Mass, Bone Loss and Prevalence of Vertebral Fracture: Differences in Postmenopausal Women and Men. <i>Osteoporosis International</i> , 1999, 10, 175-182.	1.3	50
63	Osteoporosis and adynamic bone in chronic kidney disease. <i>Journal of Nephrology</i> , 2013, 26, 73-80.	0.9	50
64	Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3479-3484.	0.4	49
65	Influence of Body Mass Index on the Association of Weight Changes with Mortality in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1725-1733.	2.2	49
66	Hypokinetic azotemic osteodystrophy. <i>Kidney International</i> , 1998, 54, 1000-1016.	2.6	48
67	Falls explain between-center differences in the incidence of limb fracture across Europe. <i>Bone</i> , 2002, 31, 712-717.	1.4	47
68	Atomic spectrometric methods (atomic absorption and inductively coupled plasma atomic emission) for the determination of aluminium at the parts per billion level in biological fluids. <i>Journal of Analytical Atomic Spectrometry</i> , 1987, 2, 177.	1.6	46
69	Height and body mass index in oslo, norway, compared to other regions of europe: do they explain differences in the incidence of hip fracture?. <i>Bone</i> , 1995, 17, 347-350.	1.4	46
70	Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. <i>Current Medical Research and Opinion</i> , 2007, 23, 3041-3045.	0.9	46
71	Effect of aluminium load on parathyroid hormone synthesis. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 742-745.	0.4	42
72	The challenge of controlling phosphorus in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 541-547.	0.4	42

#	ARTICLE	IF	CITATIONS
73	High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 934-941.	0.4	42
74	Role of the RANK/RANKL/OPG and Wnt/ β 2-Catenin Systems in CKD Bone and Cardiovascular Disorders. <i>Calcified Tissue International</i> , 2021, 108, 439-451.	1.5	41
75	Determinants of incidence of osteoporotic fractures in the female Spanish population older than 50. <i>Osteoporosis International</i> , 2005, 16, 2013-2017.	1.3	40
76	Regulation of miR-29b and miR-30c by vitamin D receptor activators contributes to attenuate uraemia-induced cardiac fibrosis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1831-1840.	0.4	40
77	Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1875-1878.	0.4	39
78	Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). <i>Nefrología</i> , 2011, 31 Suppl 1, 3-32.	0.2	37
79	Vitamin D Receptor Activation and Left Ventricular Hypertrophy in Advanced Kidney Disease. <i>American Journal of Nephrology</i> , 2011, 33, 139-149.	1.4	36
80	Mechanisms of aluminum-induced microcytosis: Lessons from accidental aluminum intoxication. <i>Kidney International</i> , 1995, 47, 164-168.	2.6	35
81	High performance liquid chromatography methods for studying protein binding of aluminium in human serum in the absence and in the presence of desferrioxamine. <i>Clinica Chimica Acta</i> , 1990, 189, 69-79.	0.5	34
82	Hyperphosphataemia as a cardiovascular risk factor - how to manage the problem. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 16-19.	0.4	34
83	Renal amyloidosis in familial Mediterranean fever. <i>Kidney International</i> , 2004, 65, 1118-1127.	2.6	34
84	Whom to treat? The contribution of vertebral X-rays to risk-based algorithms for fracture prediction. Results from the European Prospective Osteoporosis Study. <i>Osteoporosis International</i> , 2006, 17, 1369-1381.	1.3	34
85	A new role for vitamin D receptor activation in chronic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F1502-F1509.	1.3	32
86	Plasma Cardiotrophin-1 as a Marker of Hypertension and Diabetes-Induced Target Organ Damage and Cardiovascular Risk. <i>Medicine (United States)</i> , 2015, 94, e1218.	0.4	31
87	A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-Da€a”a randomised multicentre international clinical trial. <i>BMC Medicine</i> , 2022, 20, 83.	2.3	31
88	A comparison of albumin, polygeline and crystalloid priming solutions for cardiopulmonary bypass in patients having coronary artery bypass graft surgery. <i>Perfusion (United Kingdom)</i> , 1995, 10, 415-424.	0.5	30
89	Mitochondrial DNA and TFAM gene variation in early-onset myocardial infarction: Evidence for an association to haplogroup H. <i>Mitochondrion</i> , 2011, 11, 176-181.	1.6	29
90	Low calcidiol levels and risk of progression of aortic calcification. <i>Osteoporosis International</i> , 2012, 23, 1177-1182.	1.3	29

#	ARTICLE	IF	CITATIONS
91	Influence of polymorphisms in VDR and COLIA1 genes on the risk of osteoporotic fractures in aged men. <i>Kidney International</i> , 2003, 63, S14-S18.	2.6	28
92	Prevention of aluminium exposure through dialysis fluids. Analysis of changes in the last 8 years. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 78-81.	0.4	27
93	Geographic and other determinants of BMD change in European men and women at the hip and spine. A population-based study from the Network in Europe for Male Osteoporosis (NEMO). <i>Bone</i> , 2007, 40, 662-673.	1.4	27
94	Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study. <i>Nefrología</i> , 2013, 33, 46-60.	0.2	27
95	Effects of calcitriol and paricalcitol on renal fibrosis in CKD. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 793-803.	0.4	26
96	Prevalence of osteoporosis in men and determinants of changes in bone mass in a non-selected Spanish population. <i>Osteoporosis International</i> , 2005, 16, 603-609.	1.3	25
97	Childhood Fractures Do Not Predict Future Fractures: Results From the European Prospective Osteoporosis Study. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1314-1318.	3.1	25
98	Different Patterns of Renal Osteodystrophy in Iberoamerica. <i>American Journal of the Medical Sciences</i> , 2000, 320, 76-80.	0.4	24
99	Aluminum Exposure in Chronic Renal Failure in Iberoamerica at the End of the 1990s: Overview and Perspectives. <i>American Journal of the Medical Sciences</i> , 2000, 320, 96-99.	0.4	24
100	Chapter 1: Introduction and definition of CKD-MBD and the development of the guideline statements. <i>Kidney International</i> , 2009, 76, S3-S8.	2.6	24
101	Identification, cloning and characterization of an aldo-keto reductase from <i>Trypanosoma cruzi</i> with quinone oxido-reductase activity. <i>Molecular and Biochemical Parasitology</i> , 2010, 173, 132-141.	0.5	24
102	Aluminum-Induced Osteogenesis in Osteopenic Rats with Normal Renal Function. <i>Calcified Tissue International</i> , 1999, 64, 534-541.	1.5	23
103	Lanthanum activates calcium-sensing receptor and enhances sensitivity to calcium. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2930-2937.	0.4	23
104	Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 673-681.	0.4	23
105	Binding of aluminium to plasma proteins: Comparative effect of desferrioxamine and deferiprone (L1). <i>Clinica Chimica Acta</i> , 1994, 230, 137-145.	0.5	22
106	Epidemiology of renal osteodystrophy in Iberoamerica. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 41-45.	0.4	22
107	Progression of secondary hyperparathyroidism involves deregulation of genes related to DNA and RNA stability. <i>Kidney International</i> , 2005, 67, 2267-2279.	2.6	22
108	Calcium in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, S1-S2.	2.2	22

#	ARTICLE	IF	CITATIONS
109	Ultrafiltrable aluminium after very low doses of desferrioxamine. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 1538-1542.	0.4	21
110	Matrix metalloproteinase 1 promoter polymorphisms and risk of myocardial infarction: a case-control study in a Spanish population. <i>Coronary Artery Disease</i> , 2009, 20, 383-386.	0.3	21
111	Differential effects of 17 β -estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency. <i>Menopause</i> , 2010, 17, 766-771.	0.8	21
112	Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). <i>Journal of Nephrology</i> , 2008, 21, 290-8.	0.9	21
113	Effects of Menstrual History and Use of Medications on Bone Mineral Density: The EVOS Study. <i>Calcified Tissue International</i> , 1998, 63, 271-276.	1.5	20
114	The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. <i>Clinical Trials</i> , 2011, 8, 165-174.	0.7	20
115	Association of matrix Gla protein gene functional polymorphisms with loss of bone mineral density and progression of aortic calcification. <i>Osteoporosis International</i> , 2014, 25, 1237-1246.	1.3	20
116	Reconsidering the Importance of Long-Term Low-Level Aluminum Exposure in Renal Failure Patients. <i>Seminars in Dialysis</i> , 2001, 14, 5-7.	0.7	19
117	A novel mutation in the calcium-sensing receptor responsible for autosomal dominant hypocalcemia in a family with two uncommon parathyroid hormone polymorphisms. <i>Journal of Molecular Endocrinology</i> , 2003, 31, 255-262.	1.1	19
118	The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, i2-i6.	1.4	19
119	Vascular Calcification in Patients with Chronic Kidney Disease: Types, Clinical Impact and Pathogenesis. <i>Medical Principles and Practice</i> , 2011, 20, 203-212.	1.1	19
120	Vertebral Scheuermann's disease in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over. <i>Osteoporosis International</i> , 2015, 26, 2509-2519.	1.3	19
121	Chronic kidney disease-mineral and bone disorder: a complex scenario. <i>Nefrologia</i> , 2011, 31, 514-9.	0.2	19
122	Pathophysiology of Vascular Calcification and Bone Loss: Linked Disorders of Ageing?. <i>Nutrients</i> , 2021, 13, 3835.	1.7	19
123	Effect of aluminium on calcium-sensing receptor expression, proliferation, and apoptosis of parathyroid glands from rats with chronic renal failure. <i>Kidney International</i> , 2003, 63, S39-S43.	2.6	18
124	PATHOGENESIS OF BONE AND MINERAL RELATED DISORDERS IN CHRONIC KIDNEY DISEASE: KEY ROLE OF HYPERPHOSPHATEMIA. <i>Journal of Renal Care</i> , 2009, 35, 34-38.	0.6	18
125	Natural antioxidants and vascular calcification: a possible benefit. <i>Journal of Nephrology</i> , 2011, 24, 669-672.	0.9	18
126	Phosphorus and Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 234-236.	3.0	17

#	ARTICLE	IF	CITATIONS
127	H ₂ O ₂ Regulation of Vascular Function Through sGC mRNA Stabilization by HuR. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 567-573.	1.1	17
128	Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 23-28.	0.4	16
129	Aluminium removal with the double chamber technique: paired filtration-dialysis (PFD). <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 82-87.	0.4	16
130	Response of parathyroid glands to calcitriol in culture: Is this response mediated by the genetic polymorphisms in vitamin D receptor?. <i>Kidney International</i> , 2003, 63, S19-S22.	2.6	16
131	Aluminum posttranscriptional regulation of parathyroid hormone synthesis: A role for the calcium-sensing receptor. <i>Kidney International</i> , 2005, 68, 2484-2496.	2.6	16
132	Barley- β -glucans reduce systemic inflammation, renal injury and aortic calcification through ADAM17 and neutral-sphingomyelinase2 inhibition. <i>Scientific Reports</i> , 2019, 9, 17810.	1.6	16
133	Prevention, diagnosis and treatment of renal osteodystrophy in Spain. Preliminary results from a multicentre enquiry. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 51-56.	0.4	15
134	Effects of estradiol, calcitriol and both treatments combined on bone histomorphometry in rats with chronic kidney disease and ovariectomy. <i>Bone</i> , 2007, 41, 614-619.	1.4	15
135	Dual-Specificity Phosphatases Are Implicated in Severe Hyperplasia and Lack of Response to FGF23 of Uremic Parathyroid Glands from Rats. <i>Endocrinology</i> , 2012, 153, 1627-1637.	1.4	15
136	Micellar versus reversed phase liquid chromatography for the determination of desferrioxamine and its chelates with aluminium and iron in uremic serum. <i>Talanta</i> , 1997, 45, 25-33.	2.9	14
137	Lack of Association between Endothelin-1 Gene Variants and Myocardial Infarction. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009, 16, 388-395.	0.9	14
138	Pathogenesis, prevention and management of low-bone turnover. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 15-17.	0.4	13
139	Effect of VDR gene polymorphisms on osteocalcin secretion in calcitriol-stimulated human osteoblasts. <i>Kidney International</i> , 2003, 63, S23-S27.	2.6	13
140	New polymorphisms in human MEF2C gene as potential modifier of hypertrophic cardiomyopathy. <i>Molecular Biology Reports</i> , 2012, 39, 8777-8785.	1.0	13
141	Variants in cardiac <i>GATA</i> genes associated with bicuspid aortic valve. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13027.	1.7	13
142	The receptor activator of nuclear factor κ B ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 618-631.	0.4	13
143	The influence of transpulmonary pressure on the diameter of small arterial blood vessels in the lung. <i>Microvascular Research</i> , 1976, 11, 57-66.	1.1	12
144	Vitamin D receptor gene (VDR) polymorphisms: effect on bone mass, bone loss and parathyroid hormone regulation. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 73-77.	0.4	11

#	ARTICLE	IF	CITATIONS
145	Targeted genomic disruption of H-ras and N-ras has no effect on early renal changes after unilateral ureteral ligation. <i>World Journal of Urology</i> , 2009, 27, 787-797.	1.2	11
146	Estrogens and bone disease in chronic kidney disease: role of FGF23. <i>Current Opinion in Nephrology and Hypertension</i> , 2010, 19, 354-358.	1.0	11
147	An improved wave-vector frequency-domain method for nonlinear wave modeling. <i>IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control</i> , 2014, 61, 515-524.	1.7	11
148	Vitamin D Receptor Polymorphism and DHCR7 Contribute to the Abnormal Interplay Between Vitamin D and Lipid Profile in Rheumatoid Arthritis. <i>Scientific Reports</i> , 2019, 9, 2546.	1.6	11
149	Management of Secondary Hyperparathyroidism: The Gap between Diagnosis and Treatment. <i>American Journal of the Medical Sciences</i> , 2000, 320, 107-111.	0.4	10
150	2010 - GuAa de prÁctica clÁnica de la Sociedad EspaA±ola de DiÁlisis y Trasplante de las alteraciones del metabolismo mineral y A³seo de la enfermedad renal crÁnica (CKD-MBD). <i>Dialisis Y Trasplante</i> , 2011, 32, 108-118.	0.4	9
151	Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells. <i>Modern Pathology</i> , 2011, 24, 698-707.	2.9	9
152	Amadori products promote cellular senescence activating insulin-like growth factor-1 receptor and down-regulating the antioxidant enzyme catalase. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 1255-1264.	1.2	9
153	A subset of low density granulocytes is associated with vascular calcification in chronic kidney disease patients. <i>Scientific Reports</i> , 2019, 9, 13230.	1.6	9
154	Long-term response of cultured rat parathyroid glands to calcium and calcitriol: the effect of cryopreservation. <i>Journal of Nephrology</i> , 2005, 18, 141-7.	0.9	9
155	New therapies: calcimimetics, phosphate binders and vitaminA±D receptor activators. <i>Pediatric Nephrology</i> , 2010, 25, 609-616.	0.9	8
156	Supplementation of vitamin D and calcium: advantages and risks**Reference of original article: Jackson RD et al. Calcium plus Vitamin D supplementation and the risk of fractures. <i>N Engl J Med</i> 2006; 354: 669A±683.. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2375-2377.	0.4	7
157	Viability and Functionality of Fresh and Cryopreserved Human Hyperplastic Parathyroid Tissue Tested in vitro. <i>American Journal of Nephrology</i> , 2008, 28, 76-82.	1.4	7
158	The future of European Nephrology 'Guidelines'--a declaration of intent by European Renal Best Practice (ERBP). <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 213-221.	1.4	7
159	Should cinacalcet be used in patients who are not on dialysis?. <i>Nature Reviews Nephrology</i> , 2009, 5, 307-308.	4.1	7
160	Low transcriptional activity haplotype of matrix metalloproteinase 1 is less frequent in bicuspid aortic valve patients. <i>Gene</i> , 2013, 524, 304-308.	1.0	7
161	The hypercalcaemia of CYP24A1 inactivation: new ways to improve diagnosis and treatment: Fig.A±1.. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 456-458.	1.4	7
162	Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1770-1779.	1.4	7

#	ARTICLE	IF	CITATIONS
163	REGIONAL VASCULAR RESPONSE TO HYPOXIA IN THE LUNGS OF ANAESTHETISED SHEEP. The Australian Journal of Experimental Biology and Medical Science, 1974, 52, 801-812.	0.7	6
164	Exploratory investigations on the potential of radiofrequency glow discharge-optical emission spectrometry for the direct elemental analysis of bone. Journal of Analytical Atomic Spectrometry, 2001, 16, 250-255.	1.6	6
165	Bicuspid aortic valve syndrome: A heterogeneous and still unknown condition. International Journal of Cardiology, 2014, 177, 1105.	0.8	6
166	Rare Genetic Variants in Gata Transcription Factors in Patients with Hypertrophic Cardiomyopathy. Journal of Investigative Medicine, 2017, 65, 926-934.	0.7	6
167	Use of ultrafiltration and chromatography to assess aluminum speciation in serum after deferoxamine administration. American Journal of Kidney Diseases, 2000, 36, 969-975.	2.1	5
168	Proyecto COSMOS: escenario de la hemodiálisis en Europa. Nefrologia, 2016, 36, 381-388.	0.2	5
169	Time course and functional correlates of post-transplant aluminium elimination. Nephrology Dialysis Transplantation, 1998, 13, 98-102.	0.4	4
170	Updated programme for harmonization of training in nephrology in the European Union. CKJ: Clinical Kidney Journal, 2013, 6, 116-121.	1.4	4
171	Phosphate Binders and Clinical Outcomes in Patients with Stage 5D Chronic Kidney Disease. Seminars in Dialysis, 2015, 28, 587-593.	0.7	4
172	What should the characteristics and attributes of an accredited nephrology training programme be? Looking for high standards: Table 1.. CKJ: Clinical Kidney Journal, 2016, 9, 23-28.	1.4	4
173	Changing the current terminology in medicine—Always a challenge. Nephrology Dialysis Transplantation, 2007, 22, 1811-1812.	0.4	3
174	Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients. Nefrologia, 2018, 38, 520-527.	0.2	3
175	Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients. Nefrologia, 2018, 38, 520-527.	0.2	3
176	Influencia de la sobrecarga de calcio sobre el metabolismo Óseo y mineral en 55 centros de hemodiálisis de Lima. Nefrologia, 2018, 38, 279-285.	0.2	3
177	The European Certificate in Nephrology: towards harmonization and excellence in training. CKJ: Clinical Kidney Journal, 2019, 12, 167-171.	1.4	3
178	Renal osteodystrophy in Iberoamerica. American Journal of Kidney Diseases, 1999, 34, lviii-lx.	2.1	2
179	Iron Deficiency and Intestinal Aluminium Absorption: Implications for Erythropoietin and Deferoxamine Therapy. Seminars in Dialysis, 1991, 4, 224-226.	0.7	2
180	Osteoporosis therapy—time to consider renal function. Nature Reviews Endocrinology, 2011, 7, 440-441.	4.3	2

#	ARTICLE	IF	CITATIONS
181	COSMOS Project: Haemodialysis scenario in Europe. <i>Nefrologia</i> , 2016, 36, 381-388.	0.2	2
182	Mineral and Bone Disorders in Chronic Kidney Disease. , 2014, , 223-239.		2
183	Contribution of phosphorus and PTH to the development of cardiac hypertrophy and fibrosis in an experimental model of chronic renal failure. <i>Nefrologia</i> , 2021, 41, 640-651.	0.2	2
184	Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). Introduction. <i>Nefrologia</i> , 2011, 31 Suppl 1, 1-2.	0.2	2
185	REFOS study: efficacy and safety of lanthanum carbonate in clinical practice in Spain. <i>Nefrologia</i> , 2014, 34, 360-8.	0.2	2
186	Bone Aluminum Uptake in Uremic Rats Receiving Intraperitoneal Iron. <i>Biological Trace Element Research</i> , 2001, 84, 129-137.	1.9	1
187	Residue 826 in the Calcium-Sensing Receptor Is Implicated in the Response to Calcium and to R-568 Calcimimetic Compound. <i>Calcified Tissue International</i> , 2010, 86, 227-233.	1.5	1
188	Parathyroid gland regulation: contribution of the <i>in vivo</i> and <i>in vitro</i> models. <i>Expert Opinion on Drug Discovery</i> , 2010, 5, 265-275.	2.5	1
189	Aortic stenosis: A complex, atherosclerosis-like, multifactorial disease. <i>International Journal of Cardiology</i> , 2013, 168, 2966.	0.8	1
190	Clinical relevance and future perspective of fractures in patients with chronic kidney disease. <i>Kidney International</i> , 2018, 93, 1248.	2.6	1
191	Vitamin D and Renal Disease. , 2018, , 445-469.		1
192	Impact of calcium overload on bone and mineral metabolism at 55 hemodialysis centers in Lima. <i>Nefrologia</i> , 2018, 38, 279-285.	0.2	1
193	The First European Renal Association-European Dialysis and Transplant Association CKD Anaemia Physician Behaviours Survey: key findings. <i>Journal of Nephrology</i> , 2008, 21, 190-6.	0.9	1
194	Spanish nephrologists and the management of mineral and bone metabolism disorders in chronic kidney disease. <i>Nefrologia</i> , 2014, 34, 175-88.	0.2	1
195	Renal Osteodystrophy: An Update. <i>American Journal of the Medical Sciences</i> , 2000, 320, 75.	0.4	0
196	Advances in Renal Osteodystrophy” IV International Symposium. <i>Kidney International</i> , 2003, 63, S1.	2.6	0
197	Note from the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 474-474.	0.4	0
198	ERA-EDTA--a dynamic association moving forward. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3024-3025.	0.4	0

#	ARTICLE	IF	CITATIONS
199	Comment on Freemantle et al.: Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments. Osteoporosis International, 2013, 24, 1929-1930.	1.3	0
200	FP580MUSCLE STRENGTH, MUSCLE MASS AND ARTERIAL STIFFNESS IN PERITONEAL DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii267-iii267.	0.4	0
201	MP344THE INTERDIALYTIC PERIOD FOR BLOOD COLLECTION INFLUENCES SERUM PHOSPHORUS AND THE RISK OF MORTALITY IN THE COSMOS STUDY. Nephrology Dialysis Transplantation, 2016, 31, i454-i454.	0.4	0
202	Contribuci3n de f3sforo y PTH al desarrollo de hipertrofia y fibrosis card3aca en un modelo experimental de insuficiencia renal cr3nica. Nefrologia, 2021, 41, 640-651.	0.2	0
203	FC 079HIGH SERUM PHOSPHATE, A NOVEL POTENTIAL RISK FACTOR FOR BONE FRAGILITY FRACTURES IN THE COSMOS STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
204	Survival with low- and high-flux dialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1915-1923.	1.4	0